[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0015490A - Oncolytic combinations for the treatment of cancer - Google Patents

Oncolytic combinations for the treatment of cancer

Info

Publication number
BR0015490A
BR0015490A BR0015490-3A BR0015490A BR0015490A BR 0015490 A BR0015490 A BR 0015490A BR 0015490 A BR0015490 A BR 0015490A BR 0015490 A BR0015490 A BR 0015490A
Authority
BR
Brazil
Prior art keywords
cancer
treatment
combinations
oncolytic
oncolytic combinations
Prior art date
Application number
BR0015490-3A
Other languages
Portuguese (pt)
Inventor
Jerome Herbert Fleisch
Roger Stuart Benjamin
Jason Scott Sawyer
Beverly Ann Teicher
Douglas Wade Beight
Edward C R Smith
William Thomas Mcmillen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0015490A publication Critical patent/BR0015490A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

"COMBINAçõES ONCOLìTICAS PARA O TRATAMENTO DE CâNCER". Os antagonistas de leucotrieno (LTB~4~) realçam a eficácia de agentes anticâncer de 2',2'-difluoronucleosídeo."ONCOLOGICAL COMBINATIONS FOR THE TREATMENT OF CANCER". Leukotriene antagonists (LTB ~ 4 ~) enhance the efficacy of 2 ', 2'-difluoronucleoside anticancer agents.

BR0015490-3A 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer BR0015490A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16478699P 1999-11-11 1999-11-11
PCT/US2000/031039 WO2001034137A2 (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR0015490A true BR0015490A (en) 2002-07-09

Family

ID=22596085

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015490-3A BR0015490A (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer

Country Status (22)

Country Link
EP (1) EP1231938A2 (en)
JP (1) JP2003513916A (en)
KR (1) KR20020069512A (en)
CN (1) CN1390139A (en)
AR (1) AR032432A1 (en)
AU (1) AU778829B2 (en)
BR (1) BR0015490A (en)
CA (1) CA2391416A1 (en)
CZ (1) CZ20021551A3 (en)
EA (1) EA200200545A1 (en)
HK (1) HK1050132A1 (en)
HU (1) HUP0204449A3 (en)
IL (1) IL148579A0 (en)
MX (1) MXPA02004733A (en)
NO (1) NO20022245L (en)
NZ (1) NZ517667A (en)
PE (1) PE20010701A1 (en)
PL (1) PL355172A1 (en)
SK (1) SK6492002A3 (en)
TR (1) TR200201245T2 (en)
WO (1) WO2001034137A2 (en)
ZA (1) ZA200202822B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034197A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034198A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
US6797723B1 (en) 1999-11-11 2004-09-28 Eli Lilly And Company Heterocycle substituted diphenyl leukotriene antagonists
JP2001247459A (en) 2000-03-03 2001-09-11 Oakland Uniservices Ltd Combination therapy for cancer
KR20030019372A (en) * 2000-05-09 2003-03-06 크레이톤 유니버시티 Methods for inhibiting proliferation and inducing apoptosis in cancer cells
JP2004505047A (en) 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド Cancer treatment by combined therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
US7968723B2 (en) 2004-05-05 2011-06-28 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
CN1302782C (en) * 2005-01-17 2007-03-07 北京京卫燕康药物研究所有限公司 Jixitabing hydrochloride solution type injection agent
EP2298742B1 (en) 2005-06-30 2014-01-08 High Point Pharmaceuticals, LLC phenoxy acetic acids as PPAR delta activators
EP2386540A1 (en) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
EP1999098A2 (en) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Compounds that modulate ppar activity, their preparation and use
JP5207972B2 (en) 2006-10-12 2013-06-12 株式会社医薬分子設計研究所 Carboxylic acid derivatives
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
WO2014060381A1 (en) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclic compounds as pesticides
BR112015009751A2 (en) 2012-10-31 2017-07-11 Bayer Cropscience Ag new heterocyclic compounds as pesticides
CN103319466B (en) * 2013-07-04 2016-03-16 郑州大学 Containing the 1,2,3-triazoles-dithiocarbamates compound of tonka bean camphor parent nucleus, preparation method and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation

Also Published As

Publication number Publication date
ZA200202822B (en) 2003-09-23
CZ20021551A3 (en) 2003-02-12
HK1050132A1 (en) 2003-06-13
TR200201245T2 (en) 2004-08-23
JP2003513916A (en) 2003-04-15
CN1390139A (en) 2003-01-08
IL148579A0 (en) 2002-09-12
NO20022245L (en) 2002-07-09
PE20010701A1 (en) 2001-07-07
EA200200545A1 (en) 2002-12-26
AR032432A1 (en) 2003-11-12
AU778829B2 (en) 2004-12-23
AU1599001A (en) 2001-06-06
WO2001034137A3 (en) 2002-02-14
CA2391416A1 (en) 2001-05-17
HUP0204449A2 (en) 2003-04-28
MXPA02004733A (en) 2002-08-30
NZ517667A (en) 2004-05-28
PL355172A1 (en) 2004-04-05
WO2001034137A2 (en) 2001-05-17
EP1231938A2 (en) 2002-08-21
NO20022245D0 (en) 2002-05-10
KR20020069512A (en) 2002-09-04
SK6492002A3 (en) 2003-09-11
HUP0204449A3 (en) 2006-02-28

Similar Documents

Publication Publication Date Title
BR0015490A (en) Oncolytic combinations for the treatment of cancer
MA26782A1 (en) PYRAZOLOBENZODIAZEPINES AS CDK2 INHIBITORS.
PT1193270E (en) PYRROLOBENZODIAZEPINAS
ID27265A (en) Wear once
DK1114032T3 (en) 4-Amino-substituted-2-substituted-1,2,3,4-tetrahydroquinolines as CETB inhibitors
PT960107E (en) 6-TIO-SUBSTITUTED PACLITAXEL COMPOUNDS
DE60213276D1 (en) 1,2,4-thiadiazolium compounds as melanocortinreceptor modulators
ID27095A (en) Wear once
ID28132A (en) Wear once
NO992102D0 (en) Peptide composition, as well as pharmaceutical composition and cancer vaccine including the peptide composition
NO20040516L (en) Combination therapy for the treatment of cancer.
BR0013417B1 (en) aqueous composition.
BR0114903A (en) 7-azaindoles, their application as phosphodiesterase 4 inhibitors and processes for their preparation
BR0109542A (en) Alkylated imidazopyrine derivatives
ID28504A (en) Wear once
ID26456A (en) Wear once
IT1311921B1 (en) PHARMACEUTICAL COMPOUNDS.
BR0007922A (en) Calcilic compounds
WO2001034198A3 (en) Oncolytic combinations for the treatment of cancer
IT1306165B1 (en) USE OF INHIBITORS OF THE SUBSTANCE P FOR THE TREATMENT OF DENOCARCINOMAS.
TR200302134T4 (en) Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid and / or physiologically acceptable salts thereof as anti-cancer agents.
ZA200205470B (en) Virus strains for the oncolytic treatment of cancer.
BR0017046A (en) Use of azoles to prevent skin cancer
NO20020914D0 (en) Alkoxy-substituted benzimidazole compounds, preparations containing them and their applications
NO20021718L (en) Substituted pyrrols as antiproliferative agents for the treatment of cancer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8 ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.